The inclusion of three rapid oral presentations at ASCO signals strong clinical data and scientific interest, which could enhance investor confidence and support valuation ahead of upcoming regulatory decisions. Monitor for data disclosures at the conference in late May.
Price Chart
Executive Summary
Ascentage Pharma announced that six abstracts from clinical studies of its key drug candidates will be presented at the 2026 ASCO Annual Meeting, including three rapid oral presentations. This highlights the clinical progress and global recognition of its oncology pipeline.
Key Facts
- Six abstracts from clinical studies selected for presentation at ASCO 2026.
- Three rapid oral presentations and three poster presentations included.
- Presentations feature data on Olverembatinib, Lisaftoclax, and Alrizomadlin across multiple cancer types.
- ASCO is the premier global oncology conference, providing significant visibility.
Financial Impact
Non-material to near-term financials but positive for long-term value perception and partnership potential.
Risk Factors
- Clinical data may not meet expectations when presented.
- Regulatory approvals in the U.S. remain pending; FDA has not yet approved Olverembatinib, Lisaftoclax, or Alrizomadlin.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-046415 |
| Document: ea028732001ex99-2.htm | 0001213900-26-046415 |
| Document: ea0287320-6k_ascentage.htm | 0001213900-26-046415 |
| Document: 0001213900-26-046415-index-headers.html | 0001213900-26-046415 |
| Document: 0001213900-26-046415-index.html | 0001213900-26-046415 |
| Document: 0001213900-26-046415.txt | 0001213900-26-046415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.77 (−4.34%) |
Oct 21, 2026 5d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.77 (−1.01%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.77 (+0.54%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.77 (+3.90%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.77 (+14.72%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.77 (−12.37%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.77 (−12.11%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.77 (−21.81%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.77 (−19.60%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.77 (−23.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers